Multiple outlets report that the U.S. Food and Drug Administration is nearing approval of what would be the first blood test designed to screen for multiple types of cancer. NPR reports that FDA review is close to completion, with a potential decision expected by the end of the year. The test is described as a multi-cancer detection approach, intended to identify signals that may indicate the presence of different cancers rather than screening for a single cancer type. If approved, the test would represent a shift in how clinicians and public health efforts could screen for cancer, potentially offering a broader screening tool than existing options. Coverage also suggests that availability could expand after an FDA decision, though details about timing for wide use are not provided. The reporting frames the development as part of ongoing efforts to improve early detection and, ultimately, outcomes for people diagnosed with cancer. All accounts emphasize the same point: FDA approval is the key next step before the test can reach patients and health systems at scale.